CoChat

Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial

Open access
Ogino, Shuji, Liao, Xiaoyun, Imamura, Yu, Yamauchi, Mai, McCleary, Nadine J., Ng, Kimmie, Niedzwiecki, Donna, Saltz, Leonard B., Mayer, Robert J., Whittom, Renaud, Hantel, Alexander, Benson, Al B., Mowat, Rex B., Spiegelman, Donna, Goldberg, Richard M., Bertagnolli, Monica M., Meyerhardt, Jeffrey A., Fuchs, Charles S. · 2013 · JNCI: Journal of the National Cancer Institute
Cited by 49

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Somatic mutations in PIK3CA (phosphatidylinositol-4,5-bisphosphonate 3-kinase [PI3K], catalytic subunit alpha gene) activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies, including colorectal cancer. METHODS: We examined associations of PIK3CA oncogene mutation with relapse, survival, and treatment efficacy in 627 stage III colon carcinoma case subjects within a randomized adjuvant chemotherapy trial (5-fluorouracil and leucovorin [FU/LV] vs irinotecan [CPT11], fluorouracil and leucovorin [IFL]; Cancer and Leukemia Group B 89803 [Alliance]). We detected PIK3CA mutation in exons 9 and 20 by polymerase chain reaction and pyrosequencing. Cox proportional hazards model was used to assess prognostic and predictive role of PIK3CA mutation, adjusting for clinical features and status of routine standard molecular pathology features, including KRAS and BRAF mutations and microsatellite instability (mismatch repair deficiency). All statistical tests were two-sided. RESULTS: Compared with PIK3CA wild-type cases, overall status of PIK3CA mutation positivity or the presence of PIK3CA mutation in either exon 9 or 20 alone was not statistically significantly associated with recurrence-free, disease-free, or overall survival (log-rank P > .70; P > .40 in multivariable regression models). There was no statistically significant interaction between PIK3CA and KRAS (or BRAF) mutation status in survival analysis (P(interaction) > .18). PIK3CA mutation status did not appear to predict better or worse response to IFL therapy compared with FU/LV therapy (P(interaction) > .16). CONCLUSIONS: Overall tumor PIK3CA mutation status is not associated with stage III colon cancer prognosis. PIK3CA mutation does not appear to serve as a predictive tumor molecular biomarker for response to irinotecan-based adjuvant chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djt298

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 49

Metadata

Authors
Ogino, S., Liao, X., Imamura, Y., Yamauchi, M., McCleary, N. J., Ng, K., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Whittom, R., Hantel, A., Benson, A. B., Mowat, R. B., Spiegelman, D., Goldberg, R. M., Bertagnolli, M. M., Meyerhardt, J. A., & Fuchs, C. S.
Venue
JNCI: Journal of the National Cancer Institute
Published
2013-11-14
Volume
105
Issue
23
Pages
1789-1798
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2144496040
Cited by
49
References
11
FWCI
3.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial. https://app.cochat.ai/papers/10.1093/jnci/djt298
The paper
Ogino, S., Liao, X., Imamura, Y., Yamauchi, M., McCleary, N. J., Ng, K., Niedzwiecki, D., Saltz, L. B., Mayer, R. J., Whittom, R., Hantel, A., Benson, A. B., Mowat, R. B., Spiegelman, D., Goldberg, R. M., Bertagnolli, M. M., Meyerhardt, J. A., & Fuchs, C. S. (2013). Predictive and Prognostic Analysis of PIK3CA Mutation in Stage III Colon Cancer Intergroup Trial. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt298

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.